Literature DB >> 27326019

Positive inotropes in heart failure: a review article.

Ahmad Amin1, Majid Maleki2.   

Abstract

Increasing myocardial contractility has long been considered a big help for patients with systolic heart failure, conferring an augmented haemodynamic profile in terms of higher cardiac output, lower cardiac filling pressure and better organ perfusion. Though concerns have been raised over the safety issues regarding the clinical trials of different inotropes in hearts with systolic dysfunction, they still stand as a main therapeutic strategy in many centres dealing with such patients. They must be used as short in duration, low in dose and stopped as early as possible. Evidence-based guidelines have provided clinicians with valuable data for better applying inotropes in heart failure patients. In this paper, the authors address clinical trials with different agents used for increasing cardiac contractility in heart failure patients. Furthermore, the authors focus on recent guidelines on making the most out of inotropes in heart failure patients.

Entities:  

Keywords:  Fallot's tetralogy; Inotropic agents; artificial heart; congenital heart disease; coronary artery disease; heart failure; heart failure with normal ejection fraction; phosphodiesterase inhibitors; rejection; risk stratification; transplantation; ventricular tachycardia; β agonists

Year:  2012        PMID: 27326019      PMCID: PMC4898603          DOI: 10.1136/heartasia-2011-010068

Source DB:  PubMed          Journal:  Heart Asia        ISSN: 1759-1104


  53 in total

1.  Peripheral vascular effects of noradrenaline, isopropylnoradrenaline and dopamine.

Authors:  M J ALLWOOD; A F COBBOLD; J GINSBURG
Journal:  Br Med Bull       Date:  1963-05       Impact factor: 4.291

2.  Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators.

Authors:  J R Hampton; D J van Veldhuisen; F X Kleber; A J Cowley; A Ardia; P Block; A Cortina; L Cserhalmi; F Follath; G Jensen; J Kayanakis; K I Lie; G Mancia; A M Skene
Journal:  Lancet       Date:  1997-04-05       Impact factor: 79.321

3.  Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors.

Authors:  S K Milfred-LaForest; J Shubert; B Mendoza; I Flores; H J Eisen; I L Piña
Journal:  Am J Cardiol       Date:  1999-10-15       Impact factor: 2.778

4.  Comparison of dopamine and norepinephrine in the treatment of shock.

Authors:  Daniel De Backer; Patrick Biston; Jacques Devriendt; Christian Madl; Didier Chochrad; Cesar Aldecoa; Alexandre Brasseur; Pierre Defrance; Philippe Gottignies; Jean-Louis Vincent
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

5.  Preliminary experience with inhaled milrinone in cardiac surgery.

Authors:  Yoan Lamarche; Louis P Perrault; Simon Maltais; Karine Tétreault; Jean Lambert; André Y Denault
Journal:  Eur J Cardiothorac Surg       Date:  2007-04-02       Impact factor: 4.191

6.  Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.

Authors:  J Lubsen; H Just; A C Hjalmarsson; D La Framboise; W J Remme; J Heinrich-Nols; J M Dumont; P Seed
Journal:  Heart       Date:  1996-09       Impact factor: 5.994

7.  Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure.

Authors:  W S McMahon; H H Holzgrefe; J D Walker; R Mukherjee; S R Arthur; M J Cavallo; M J Child; F G Spinale
Journal:  J Am Coll Cardiol       Date:  1996-08       Impact factor: 24.094

Review 8.  Pharmacology and therapeutic use of low-dose dopamine.

Authors:  J F Dasta; M G Kirby
Journal:  Pharmacotherapy       Date:  1986 Nov-Dec       Impact factor: 4.705

9.  Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure.

Authors:  E Bollano; M Scharin Täng; A Hjalmarson; F Waagstein; B Andersson
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

Review 10.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur Heart J       Date:  2008-09-17       Impact factor: 29.983

View more
  1 in total

Review 1.  Coronavirus disease 2019 and the natural agents: Is there a role for the primary care?

Authors:  Manal O Alharthi; Raghad A Alasmari; Rahaf I Almatani; Rehab M Alharthi; Suha A Aljumaiei; Bashayr A Alkuhayli; Ahmed M Kabel
Journal:  J Family Med Prim Care       Date:  2021-04-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.